January 1, 1981The Japanese Journal of PharmacologyOpen Access

A new potent inhibitor of converting enzyme: (2R,4R)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid(SA446).

View Full Paper

Ask AI

Bookmark

Population

In vitro models and in vivo animal models

Comparison

SA446 (intravenous and oral administration) vs Captopril

Design

Preclinical

Authors

TITadashi IsoNagoya University HYHideyasu YamauchiSanten (Japan)HSHiroshi SudaPanasonic (Japan)

Discussion

Member takes

Implication

SA446 merits further preclinical development as an oral ACE inhibitor; leaves open translation to human hypertension therapy.

Structured PICO

Population

In vitro models (semi-purified rabbit lung converting enzyme, isolated guinea pig ileum) and in vivo animal models (rats and dogs, including two-kidney, one-clip renal hypertensive rats, spontaneously hypertensive rats, normotensive rats, and DOCA-salt hypertensive rats)

Intervention

SA446 (intravenous and oral administration)

Comparator

Captopril (for in vitro and some in vivo comparisons)

Outcome

Inhibition of converting enzyme activity and blood pressure reductionsurrogate

SA446 is a potent novel converting enzyme inhibitor with significant antihypertensive effects in animal models.

Cite This Study

Iso et al. (1981) studied this question.

synapsesocial.com/papers/6a815f702bdcf510039cd801 https://doi.org/10.1254/jjp.31.875

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

A new potent inhibitor of converting enzyme: (2R,4R)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid(SA446).

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

A new potent inhibitor of converting enzyme: (2R,4R)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid(SA446).

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider